Usefulness of
Arginine-glycine-aspartic acid (RGD)
Fibrosis
Idiopathic pulmonary fibrosis (IPF)
Integrin
Oxygen partial pressure (pO2)
Positron emission tomography (PET)
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
20
04
2022
accepted:
07
07
2022
pubmed:
26
7
2022
medline:
29
10
2022
entrez:
25
7
2022
Statut:
ppublish
Résumé
Integrins α Pulmonary fibrosis was induced by single intratracheal instillation of bleomycin (3 mg/rat). Positron emission tomography (PET)/computerized tomography scans were performed 4 weeks after bleomycin administration using Histopathological evaluation demonstrated the development of fibrosis in IPF-model group. Integrin α Our findings demonstrate that the integrin α
Identifiants
pubmed: 35876866
doi: 10.1007/s00259-022-05908-4
pii: 10.1007/s00259-022-05908-4
doi:
Substances chimiques
Bleomycin
11056-06-7
Integrin alphaVbeta3
0
Oligopeptides
0
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4358-4368Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Gribbin J, Hubbard RB, Le Jeune I, Smith CJP, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax Thorax. 2006;61:980–5.
doi: 10.1136/thx.2006.062836
Ogura T, Taniguchi H, Azuma A, Inoue Y, Kondoh Y, Hasegawa Y, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J Eur Respir J. 2015;45:1382–92.
doi: 10.1183/09031936.00198013
Raghu G. Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential. Eur Respir Rev. Eur Respir Rev. 2017;26
Hutchinson JP, Fogarty AW, McKeever TM, Hubbard RB. In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States 2000 to 2011. Am J Respir Crit Care Med. 2016;193:1161–7.
doi: 10.1164/rccm.201508-1632OC
Souza CA, Müller NL, Flint J, Wright JL, Churg A. Idiopathic pulmonary fibrosis: spectrum of high-resolution CT findings. AJR Am J Roentgenol. 2005;185:1531–9.
Hunninghake GW, Bridget Zimmerman M, Schwartz DA, King TE, Lynch J, Hegele R, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;164:193–6.
doi: 10.1164/ajrccm.164.2.2101090
Lukey PT, Coello C, Gunn R, Parker C, Wilson FJ, Saleem A, et al. Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study). Eur J Nucl Med Mol Imaging: Springer; 2019.
Kimura RH, Wang L, Shen B, Huo L, Tummers W, Filipp FV, et al. Evaluation of integrin αvβ6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis 2019 101. Nat Commun. 2019;101(10):1–18 (Nature Publishing Group).
Wuyts WA, Wijsenbeek M, Bondue B, Bouros D, Bresser P, RobaloCordeiro C, et al. Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease. Respiration. 2020;99:73 (Karger Publishers).
doi: 10.1159/000504763
Goodwin A, Jenkins G. Role of integrin-mediated TGFbeta activation in the pathogenesis of pulmonary fibrosis. Biochem Soc Trans. 2009;37:849–54.
doi: 10.1042/BST0370849
Henderson NC, Sheppard D. Integrin-mediated regulation of TGFβ in fibrosis. Biochim Biophys Acta. 2013;1832:891–6.
Schniering J, Benešová M, Brunner M, Haller S, Cohrs S, Frauenfelder T, et al. Visualisation of interstitial lung disease by molecular imaging of integrin α v β 3 and somatostatin receptor 2. Ann Rheum Dis. 2019;78:218–27.
doi: 10.1136/annrheumdis-2018-214322
Horan GS, Wood S, Ona V, Dan JL, Lukashev ME, Weinreb PH, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med. 2008;177:56–65.
doi: 10.1164/rccm.200706-805OC
Xu MY, Porte J, Knox AJ, Weinreb PH, Maher TM, Violette SM, et al. Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol Am J Pathol. 2009;174:1264–79.
doi: 10.2353/ajpath.2009.080160
John AE, Luckett JC, Tatler AL, Awais RO, Desai A, Habgood A, et al. Preclinical SPECT/CT imaging of αvβ6 integrins for molecular stratification of idiopathic pulmonary fibrosis. J Nucl Med J Nucl Med. 2013;54:2146–52.
doi: 10.2967/jnumed.113.120592
Guo N, Lang L, Li W, Kiesewetter DO, Gao H, Niu G, et al. Quantitative analysis and comparison study of [18F]AlF-NOTA-PRGD2 [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 using a reference tissue model. PLoS One. 2012;7:37506–14.
Hiroyama S, Rokugawa T, Ito M, Iimori H, Morita I, Maeda H, et al. Quantitative evaluation of hepatic integrin αvβ3 expression by positron emission tomography imaging using 18F-FPP-RGD2 in rats with non-alcoholic steatohepatitis. EJNMMI Res. 2020;10:118–29.
Kapp TG, Rechenmacher F, Neubauer S, Maltsev OV, Cavalcanti-Adam EA, Zarka R, et al. A comprehensive evaluation of the activity and selectivity profile of ligands for RGD-binding integrins. Sci Rep. 2017;7:39805–17.
Haskali MB, Roselt PD, Karas JA, Noonan W, Wichmann CW, Katsifis A, et al. One-step radiosynthesis of 4-nitrophenyl 2-[(18) F]fluoropropionate ([(18) F]NFP); improved preparation of radiolabeled peptides for PET imaging. J Labelled Comp Radiopharm. 2013;56:726–30.
doi: 10.1002/jlcr.3111
Jin ZH, Furukawa T, Sogawa C, Claron M, Aung W, Tsuji AB, et al. PET imaging and biodistribution analysis of the effects of succinylated gelatin combined with l-lysine on renal uptake and retention of 64Cu-cyclam-RAFT-c(-RGDfK-)4 in vivo. Eur J Pharm Biopharm Elsevier. 2014;86:478–86.
doi: 10.1016/j.ejpb.2013.11.006
Bergeron M, Cadorette J, Tétrault MA, Beaudoin JF, Leroux JD, Fontaine R, et al. Imaging performance of LabPET APD-based digital PET scanners for pre-clinical research. Phys Med Biol Phys Med Biol. 2014;59:661–78.
doi: 10.1088/0031-9155/59/3/661
Holman BF, Cuplov V, Millner L, Hutton BF, Maher TM, Groves AM, et al. Improved correction for the tissue fraction effect in lung PET / CT imaging. Phys Med Biol IOP Publishing. 2015;60:7387–402.
doi: 10.1088/0031-9155/60/18/7387
Lambrou T, Groves AM, Erlandsson K, Screaton N, Endozo R, Win T, et al. The importance of correction for tissue fraction effects in lung PET: Preliminary findings. Eur J Nucl Med Mol Imaging Springer. 2011;38:2238–46.
doi: 10.1007/s00259-011-1906-x
Akaike H. A New Look at the Statistical Model Identification. IEEE Trans Autom Control Springer. 1974;19:716–23.
doi: 10.1109/TAC.1974.1100705
Persson IM, Pettersson NF, Liu J, Håkansson HF, Örbom A, Zandt RI, et al. Longitudinal imaging using pet/ct with collagen-i pet-tracer and mri for assessment of fibrotic and inflammatory lesions in a rat lung injury model. J Clin Med. 2020;9:1–21.
Tashiro J, Elliot SJ, Gerth DJ, Xia X, Pereira-Simon S, Choi R, et al. Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis. Transl Res Mosby. 2015;166:554–67.
doi: 10.1016/j.trsl.2015.09.004
Yousefi-Manesh H, Noori T, Asgardoon MH, Derakhshan MH, Tavangar SM, Sheibani M, et al. Protective effect of dapsone against bleomycin-induced lung fibrosis in rat. Exp Mol Pathol. 2022;124:104737–44.
Schniering J, Benešová M, Brunner M, Haller S, Cohrs S, Frauenfelder T, et al. Visualisation of interstitial lung disease by molecular imaging of integrin αvβ3 and somatostatin receptor 2. Ann Rheum Dis. 2019;78:218–27.
doi: 10.1136/annrheumdis-2018-214322
Lukey PT, Coello C, Gunn R, Parker C, Wilson FJ, Saleem A, et al. Clinical quantification of the integrin αvβ6 by [18 F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study). Eur J Nucl Med Mol Imaging. 2020;47:967–79.
doi: 10.1007/s00259-019-04586-z
Chu KA, Yeh CC, Kuo FH, Lin WR, Hsu CW, Chen TH, et al. Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly. Stem Cell Res Ther BioMed Central Ltd. 2020;11:1–14.
Tanguy J, Goirand F, Bouchard A, Frenay J, Moreau M, Mothes C, et al. [18 F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [18 F]FDG PET/CT approach. Eur J Nucl Med Mol Imaging. 2021;48:3058–74.
doi: 10.1007/s00259-021-05209-2